trazodone has been researched along with Disorders of Excessive Somnolence in 3 studies
Trazodone: A serotonin uptake inhibitor that is used as an antidepressive agent. It has been shown to be effective in patients with major depressive disorders and other subsets of depressive disorders. It is generally more useful in depressive disorders associated with insomnia and anxiety. This drug does not aggravate psychotic symptoms in patients with schizophrenia or schizoaffective disorders. (From AMA Drug Evaluations Annual, 1994, p309)
trazodone : An N-arylpiperazine in which one nitrogen is substituted by a 3-chlorophenyl group, while the other is substituted by a 3-(3-oxo[1,2,4]triazolo[4,3-a]pyridin-2(3H)-yl)propyl group.
Disorders of Excessive Somnolence: Disorders characterized by hypersomnolence during normal waking hours that may impair cognitive functioning. Subtypes include primary hypersomnia disorders (e.g., IDIOPATHIC HYPERSOMNOLENCE; NARCOLEPSY; and KLEINE-LEVIN SYNDROME) and secondary hypersomnia disorders where excessive somnolence can be attributed to a known cause (e.g., drug affect, MENTAL DISORDERS, and SLEEP APNEA SYNDROME). (From J Neurol Sci 1998 Jan 8;153(2):192-202; Thorpy, Principles and Practice of Sleep Medicine, 2nd ed, p320)
| Excerpt | Relevance | Reference |
|---|---|---|
| " Pitolisant, a novel histamine-3 receptor antagonist/inverse agonist, gained approval for the treatment of excessive daytime sleepiness in adults with narcolepsy as well as obstructive sleep apnea." | 5.05 | New pharmacologic agents for insomnia and hypersomnia. ( Earl, DC; Van Tyle, KM, 2020) |
| "Insomnia and daytime sleepiness are often associated with depression." | 2.42 | Daytime sleepiness and insomnia as correlates of depression. ( Fava, M, 2004) |
| "Trazodone is a clinically available anti-depressant that exhibits affinity for serotonin 1A and 2A receptors, as well as for alpha-adrenoceptors, suggesting that it may be useful to treat L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesia and psychosis that are encountered in advanced Parkinson's disease (PD)." | 1.48 | Trazodone alleviates both dyskinesia and psychosis in the parkinsonian marmoset model of Parkinson's disease. ( Gourdon, JC; Hamadjida, A; Huot, P; Nuara, SG, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Earl, DC | 1 |
| Van Tyle, KM | 1 |
| Hamadjida, A | 1 |
| Nuara, SG | 1 |
| Gourdon, JC | 1 |
| Huot, P | 1 |
| Fava, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Music to Improve Sleep Quality in Adults With Depression and Insomnia: a Randomized Controlled Trial Using Mixed Methods[NCT03676491] | 112 participants (Actual) | Interventional | 2018-05-23 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for trazodone and Disorders of Excessive Somnolence
| Article | Year |
|---|---|
New pharmacologic agents for insomnia and hypersomnia.
Topics: Azepines; Carbamates; Dementia; Disorders of Excessive Somnolence; GABA-A Receptor Agonists; Humans; | 2020 |
Daytime sleepiness and insomnia as correlates of depression.
Topics: Antidepressive Agents; Benzhydryl Compounds; Bupropion; Comorbidity; Depressive Disorder; Disorders | 2004 |
1 other study available for trazodone and Disorders of Excessive Somnolence
| Article | Year |
|---|---|
Trazodone alleviates both dyskinesia and psychosis in the parkinsonian marmoset model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Antipsychotic Agents; Behavior, Animal; Callithrix; Disorders of Exce | 2018 |